Observational studyAnnals of internal medicine2015
Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.
Observational study in Annals of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00028145 (Perinatal Core Protocol), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perinatal Core Protocol
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Antiretroviral Therapy at Conception Leads to Lower Peripheral CD49aJournal of immunology research · 2025Article
- Article
- Single-cell sequencing resolves the landscape of immune cells and regulatory mechanisms in HIV-infected immune non-responders.Cell death & disease · 2022Article
- Article
- Profile of Chronic Comorbid Conditions and Obstetrical Complications Among Pregnant Women With Human Immunodeficiency Virus and Receiving Antiretroviral Therapy in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Modeling Viral Suppression, Viral Rebound and State-Specific Duration of HIV Patients with CD4 Count Adjustment: Parametric Multistate Frailty Model Approach.Infectious diseases and therapy · 2020Article
- Time of HIV diagnosis, CD4 count and viral load at antenatal care start and delivery in South Africa.PloS one · 2020Article
- Detectable HIV-RNA Viral Load Among HIV-Infected Pregnant Women on Treatment in Northern Uganda.International journal of MCH and AIDS · 2020Article
- Better executive function is independently associated with full HIV suppression during combination therapy.AIDS (London, England) · 2019Observational
- A Multicenter Analysis of Elvitegravir Use During Pregnancy on HIV Viral Suppression and Perinatal Outcomes.Open forum infectious diseases · 2019Article
- Observational
- Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy.AIDS (London, England) · 2018Article
- Changing Patterns and Factors Associated With Mode of Delivery Among Pregnant Women With Human Immunodeficiency Virus Infection in the United States.Obstetrics and gynecology · 2018Article
- Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.The Journal of antimicrobial chemotherapy · 2018Article
- Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Open forum infectious diseases · 2017Article
- Complications and Route of Delivery in a Large Cohort Study of HIV-1-Infected Women-IMPAACT P1025.Journal of acquired immune deficiency syndromes (1999) · 2016Article
- Reported Church Attendance at the Time of Entry into HIV Care is Associated with Viral Load Suppression at 12 Months.AIDS and behavior · 2016Article
- Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.American journal of obstetrics and gynecology · 2016Article
- Factors Associated With Lack of Viral Suppression at Delivery.Annals of internal medicine · 2015Article
- Time of HIV Diagnosis and Engagement in Prenatal Care Impact Virologic Outcomes of Pregnant Women with HIV.PloS one · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundA high delivery maternal plasma HIV-1 RNA level (viral load [VL]) is a risk factor for mother-to-child transmission and poor maternal health.
objectiveTo identify factors associated with detectable VL at delivery despite initiation of highly active antiretroviral therapy (HAART) during pregnancy.
designMulticenter observational study. (ClinicalTrial.gov: NCT00028145).
setting67 U.S. AIDS clinical research sites. PATIENTS: Pregnant women with HIV who initiated HAART during pregnancy. MEASUREMENTS: Descriptive summaries and associations among sociodemographic, HIV disease, and treatment characteristics; pregnancy-related risk factors; and detectable VL (>400 copies/mL) at delivery.
resultsBetween 2002 and 2011, 671 women met inclusion criteria and 13.1% had detectable VL at delivery. Factors associated with detectable VL included multiparity (16.4% vs. 8.0% nulliparity; P = 0.002), black ethnicity (17.6% vs. 6.6% Hispanic and 6.6% white; P < 0.001), 11th grade education or less (17.6% vs. 12.1% had a high school diploma; P = 0.013), initiation of HAART in the third trimester (23.9% vs. 12.3% and 8.6% in the second and trimesters, respectively; P = 0.003), having an HIV diagnosis before the current pregnancy (16.1% vs. 11.0% during the current pregnancy; P = 0.051), and having the first prenatal visit in the third trimester (33.3% vs. 14.3% and 10.5% in the second and third trimesters, respectively; P = 0.002). Women who had treatment interruptions or reported poor medication adherence were more likely to have detectable VL at delivery. LIMITATION: Data on many covariates were incomplete because women entered the study at varying times during pregnancy.
conclusionA total of 13.1% of women who initiated HAART during pregnancy had detectable VL at delivery. The timing of HAART initiation and prenatal care, along with medication adherence during pregnancy, were associated with detectable VL at delivery. Social factors, including ethnicity and education, may help identify women who could benefit from focused efforts to promote early HAART initiation and adherence. PRIMARY FUNDING SOURCE: U.S. Department of Health and Human Services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.